Clinical trialNCT06240728RecruitingPhase 1Interventional

A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2

SponsorNextPoint Therapeutics, Inc.Enrollment144Metastatic Malignant Neoplasm

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

NPX887 is a human, antagonistic immunoglobulin G1 (IgG1) monoclonal antibody targeting B7-H7 (HHLA2) that may potentiate an anti-tumor immune response. The goal of this first-in-human study is to learn whether NPX887 is safe and tolerable and shows a preliminary efficacy in participants with B7-H7 (HHLA2) expressing tumors at selected dose(s). The main questions it aims to answer are: * what is an appropriate dose to be given to participants? * are the side effects of treatment manageable? * what is the preliminary anti-tumor activities? Participants who are treated will receive an intravenous (IV) infusion of NPX887 if their disease has not progressed, and be closely monitored by the treating physicians.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Leena Gandhi, MD, PhD
NextPoint
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

South Korea

Samsung Medical Center
Seoul, South Korea
Myung-Ju Ahn, MD
Recruiting
Severance Hospital, Yonsei University Health System
Seoul, South Korea
Byoung Chul Cho, MD
Recruiting

United States

Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, United States
Active, not recruiting
Beth Israel Deaconess Medical Center (bidmc)
Boston, Massachusetts, United States
Active, not recruiting
Albert Einstein Medical College Montefiore Medical Center
The Bronx, New York, United States
Active, not recruiting
Md Anderson Cancer Center
Houston, Texas, United States
Active, not recruiting
Next Oncology
San Antonio, Texas, United States
Active, not recruiting
Next Oncology-Fairfax
Fairfax, Virginia, United States
Active, not recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

NPX887

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 22 Jan 2024
Primary completion: 31 Aug 2027
Completion: 31 Aug 2027
Last update posted: 27 Jun 2025
Registered enrollment: 144
Registry id: NCT06240728

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.